Effect of Dexamethasone Cyclophosphamide Pulse Therapy in Collagen Vascular Diseases

Abstract

Background: Collagen vascular diseases (CVDs), a group of autoimmune disorders that affect connective tissues, are characterized by systemic inflammation. Conditions like systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitis lead to significant morbidity and often require aggressive treatment strategies. Dexamethasone cyclophosphamide pulse therapy (DCP) is one such treatment approach used to manage severe flare-ups and complications associated with CVDs.

Objective: This study aims to evaluate the effects of dexamethasone cyclophosphamide pulse therapy in the treatment of collagen vascular diseases, particularly its efficacy, safety, and impact on disease progression.

Methods: Forty patients diagnosed with severe collagen vascular diseases, including SLE, systemic sclerosis, and vasculitis, were treated with DCP therapy over a period of six months. Clinical response, side effects, and changes in disease biomarkers were monitored.

Results: Seventy percent of the patients showed improvement in disease activity, with reductions in flare-ups, organ involvement, and inflammatory markers. Side effects were observed in 30% of patients, including infections, gastrointestinal disturbances, and leukopenia.

Conclusion: Dexamethasone cyclophosphamide pulse therapy proved effective in managing severe collagen vascular diseases. Although it significantly improved clinical outcomes, side effects require careful monitoring.

Keywords: Dexamethasone, Cyclophosphamide, Pulse Therapy, Collagen Vascular Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Vasculitis, Autoimmune Diseases